SuperworthMoleculin Biotech MBRX
- Market cap
- $6.3M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/a
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $0
- Net margin
- n/a
- Free cash flow yield
- n/m
- not a meaningful number
Revenue was $0 over the last twelve months.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| R&D | $3.3M−45% | $6.6M+59% | $4.3M−25% | $4.1M+5% | $4.9M+50% | $4.5M−33% | $3.4M−19% | $3.6M−12% | $3.7M−24% | $5.1M+15% | $5.4M+57% | $5.5M+51% |
| SG&A | $2.6M−15% | $2.3M−21% | $2.4M−9% | $2.1M−17% | $2.2M−18% | $2.2M−4% | $2.5M+4% | $2.1M+1% | $2.1M−1% | $2.4M+12% | $2.5M+0% | $2.1M+1% |
| −$5.9M−35% | −$8.9M+27% | −$6.7M−20% | −$6.2M−4% | −$7.1M+20% | −$6.6M−26% | −$5.9M−11% | −$5.7M−8% | −$5.9M−17% | −$7.5M+13% | −$7.9M+33% | −$7.6M+32% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$5.6M−35% | −$10.3M+52% | −$5M−37% | −$4.3M−28% | −$7M+25% | −$1.9M−82% | −$5.9M+19% | −$17.8M+312% | −$25.4M+262% | $15.6M | −$12.8M+118% | −$7.6M−57% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EPS, diluted: 6 periods, Q4 FY16 to Q4 FY21: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY16 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Moleculin Biotech's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MBRXMoleculin Biotech | $6.3M | n/m | n/a | n/a | n/m | n/a | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| Peer median | $47.8M | 13.6× | 14.8× | 1.4× | +15% | 7.6% |
More on Moleculin Biotech
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .